Trial Profile
Open-Label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Registrational; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2024 Planned End Date changed from 30 Apr 2025 to 27 Mar 2025.
- 04 Jan 2024 Planned primary completion date changed from 30 Apr 2025 to 27 Mar 2025.